
Radius Health RDUS
Quarterly report 2022-Q2
added 08-09-2022
Radius Health Operating Cash Flow 2011-2026 | RDUS
Annual Operating Cash Flow Radius Health
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -22.4 M | -73.9 M | -82.4 M | -205 M | -207 M | -140 M | -87.1 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -22.4 M | -207 M | -117 M |
Quarterly Operating Cash Flow Radius Health
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -39.2 M | -40.2 M | - | - | -34.1 M | -19.1 M | - | -46.6 M | -46.1 M | -33.2 M | - | -75 M | -53.7 M | -34.5 M | - | -164 M | -122 M | -70.2 M | - | -167 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -19.1 M | -167 M | -67.5 M |
Operating Cash Flow of other stocks in the Drug manufacturers industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
-12.7 M | - | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
-9.58 M | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
-14.3 M | - | - | $ 142 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-25.9 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
-99.2 M | - | - | $ 754 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-46.9 M | - | - | $ 2.06 B | ||
|
Canopy Growth Corporation
CGC
|
-166 M | $ 1.17 | 1.74 % | $ 126 M | ||
|
China Pharma Holdings
CPHI
|
-466 K | $ 0.61 | -1.46 % | $ 10.7 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-612 K | $ 3.92 | 2.08 % | $ 55.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
50.7 M | - | -39.89 % | $ 27.7 M | ||
|
Catalent
CTLT
|
268 M | - | - | $ 11.5 B | ||
|
Evoke Pharma
EVOK
|
-4.98 M | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-462 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
-43.1 M | - | 2.45 % | $ 38.1 M | ||
|
Harrow Health
HROW
|
3.84 M | $ 52.78 | 2.39 % | $ 1.72 B | ||
|
DURECT Corporation
DRRX
|
-34.4 M | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
-206 M | $ 10.96 | - | $ 561 M | ||
|
Endo International plc
ENDP
|
435 M | - | - | $ 28.9 M | ||
|
Athenex
ATNX
|
-131 M | - | -23.39 % | $ 1.76 M | ||
|
Evolus
EOLS
|
-18 M | $ 4.3 | -0.69 % | $ 267 M | ||
|
Lannett Company
LCI
|
-7.12 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
-28.6 M | $ 1.42 | 1.43 % | $ 402 M | ||
|
Jupiter Wellness
JUPW
|
-7.57 M | - | - | $ 33.6 M | ||
|
Pacira BioSciences
PCRX
|
189 M | $ 23.41 | 1.3 % | $ 1.08 B | ||
|
Bausch Health Companies
BHC
|
1.03 B | $ 6.02 | - | $ 2.2 B | ||
|
Sundial Growers
SNDL
|
-155 M | $ 1.55 | 4.03 % | $ 3.37 M | ||
|
Neoleukin Therapeutics
NLTX
|
-51.4 M | - | - | $ 193 M | ||
|
Tilray
TLRY
|
7.91 M | $ 7.92 | 4.9 % | $ 4.89 B | ||
|
Organogenesis Holdings
ORGO
|
14.2 M | $ 4.03 | 2.81 % | $ 531 M | ||
|
PetIQ
PETQ
|
61.9 M | - | 1.64 % | $ 400 M | ||
|
Perrigo Company plc
PRGO
|
363 M | $ 14.61 | - | $ 2.01 B | ||
|
Aurora Cannabis
ACB
|
-211 M | $ 3.79 | 3.84 % | $ 86.3 M | ||
|
ProPhase Labs
PRPH
|
28.6 M | - | - | $ 5.07 M | ||
|
Recro Pharma
REPH
|
-1 M | - | -4.76 % | $ 65.3 M | ||
|
Rockwell Medical
RMTI
|
-9.41 M | $ 0.94 | 2.02 % | $ 21.9 M | ||
|
Relmada Therapeutics
RLMD
|
-51.7 M | $ 4.26 | 5.71 % | $ 128 M | ||
|
OptiNose
OPTN
|
-20.5 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
49.6 M | $ 11.94 | -0.83 % | $ 848 M | ||
|
PLx Pharma
PLXP
|
-32.1 M | - | -27.8 % | $ 2.56 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-88 K | $ 2.84 | - | $ 3.52 M | ||
|
Solid Biosciences
SLDB
|
-100 M | $ 6.18 | 5.28 % | $ 252 M | ||
|
SCYNEXIS
SCYX
|
60.2 M | $ 0.79 | 2.18 % | $ 37.8 M | ||
|
Tricida
TCDA
|
-140 M | - | - | $ 3.25 M | ||
|
Veru
VERU
|
-21.7 M | $ 2.61 | 5.24 % | $ 352 M | ||
|
TherapeuticsMD
TXMD
|
-159 M | $ 2.25 | -1.32 % | $ 23.5 M | ||
|
cbdMD
YCBD
|
-353 K | $ 0.93 | 1.85 % | $ 4.01 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-23 M | - | - | $ 55.5 M | ||
|
Viatris
VTRS
|
3 B | $ 16.07 | 0.72 % | $ 19.5 B |